5933-7 |
Lead |
MCnc |
Dial fld |
Pt |
Qn |
|
|
ACTIVE |
Lead [Mass/volume] in Dialysis fluid |
|
MIN |
DefinitionDescription |
|
|
ug/dL |
|
|
|
|
|
|
DRUG/TOX |
|
5933-7 |
|
|
|
|
Both |
|
|
|
0 |
Lead Dial fld-mCnc |
|
|
|
Y |
|
Diaf; Dialysate; Dialysis fluid; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Painter's colic; PB; Plumbism; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.34 |
1.0d |
|
|
|
|
|
|
|
ug/dL |
|
|
|
0 |
59330-1 |
Norsibutramine |
MCnc |
Bld |
Pt |
Qn |
|
|
ACTIVE |
Norsibutramine [Mass/volume] in Blood |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
0.1 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59330-1 |
|
|
|
|
Both |
|
|
|
0 |
Norsibutramine Bld-mCnc |
|
|
|
N |
|
Blood; Desmethylsibutramine; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; Sibutramine metabolite; WB; Whole blood |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59331-9 |
Dinorsibutramine |
MCnc |
Bld |
Pt |
Qn |
|
|
ACTIVE |
Dinorsibutramine [Mass/volume] in Blood |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
0.1 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59331-9 |
|
|
|
|
Both |
|
|
|
0 |
Dinorsibutramine Bld-mCnc |
|
|
|
N |
|
Blood; Didesmethylsibutramine; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; Sibutramine metabolite; WB; Whole blood |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59332-7 |
Sibutramine |
MCnc |
Bld |
Pt |
Qn |
|
|
ACTIVE |
Sibutramine [Mass/volume] in Blood |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
0.1 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59332-7 |
|
|
|
|
Both |
|
|
|
0 |
Sibutramine Bld-mCnc |
|
|
|
N |
|
Blood; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Meridia; Point in time; QNT; Quan; Quant; Quantitative; Random; Reductil; WB; Whole blood |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59333-5 |
Norsibutramine |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Norsibutramine [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
0.1 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59333-5 |
|
|
|
|
Both |
|
|
|
0 |
Norsibutramine SerPl-mCnc |
|
|
|
N |
|
Desmethylsibutramine; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; Sibutramine metabolite; SR |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59334-3 |
Dinorsibutramine |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Dinorsibutramine [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
0.1 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59334-3 |
|
|
|
|
Both |
|
|
|
0 |
Dinorsibutramine SerPl-mCnc |
|
|
|
N |
|
Didesmethylsibutramine; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; Sibutramine metabolite; SR |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59335-0 |
Sibutramine |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Sibutramine [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
0.1 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59335-0 |
|
|
|
|
Both |
|
|
|
0 |
Sibutramine SerPl-mCnc |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Meridia; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; Reductil; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59336-8 |
Norsibutramine |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Norsibutramine [Mass/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
0.1 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59336-8 |
|
|
|
|
Both |
|
|
|
0 |
Norsibutramine Ur-mCnc |
|
|
|
N |
|
Desmethylsibutramine; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; Sibutramine metabolite; UA; UR; Urn |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59337-6 |
Dinorsibutramine |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Dinorsibutramine [Mass/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
0.1 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59337-6 |
|
|
|
|
Both |
|
|
|
0 |
Dinorsibutramine Ur-mCnc |
|
|
|
N |
|
Didesmethylsibutramine; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; Sibutramine metabolite; UA; UR; Urn |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59338-4 |
Sibutramine |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Sibutramine [Mass/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
0.1 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59338-4 |
|
|
|
|
Both |
|
|
|
0 |
Sibutramine Ur-mCnc |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Meridia; Point in time; QNT; Quan; Quant; Quantitative; Random; Reductil; UA; UR; Urn |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59339-2 |
Stiripentol |
MCnc |
Bld |
Pt |
Qn |
|
|
ACTIVE |
Stiripentol [Mass/volume] in Blood |
|
MIN |
DefinitionDescription |
|
|
ug/mL |
0.1 mcg/mL |
|
|
|
|
|
DRUG/TOX |
|
59339-2 |
|
|
|
|
Both |
|
|
|
0 |
Stiripentol Bld-mCnc |
|
|
|
N |
|
Blood; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; WB; Whole blood |
2.7 |
2.32 |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
5934-5 |
Blood group antigens absent |
Prid |
BBL |
Pt |
Nom |
|
|
DEPRECATED |
Deprecated Blood group antigens absent [Identifier] in Blood product unit |
|
DEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
BLDBK |
|
5934-5 |
|
|
|
|
Observation |
|
|
|
0 |
Deprecated Antigens Absent BBL |
|
|
|
|
|
Ag; Blood bag; BLOOD BANK; Identity or presence; Nominal; Point in time; Random |
2.36 |
1.0d |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
59340-0 |
Stiripentol |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Stiripentol [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
ug/mL |
0.1 mcg/mL |
|
|
|
|
|
DRUG/TOX |
|
59340-0 |
|
|
|
|
Both |
|
|
|
0 |
Stiripentol SerPl-mCnc |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.7 |
2.32 |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
59341-8 |
Stiripentol |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Stiripentol [Mass/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
ug/mL |
0.1 mcg/mL |
|
|
|
|
|
DRUG/TOX |
|
59341-8 |
|
|
|
|
Both |
|
|
|
0 |
Stiripentol Ur-mCnc |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.7 |
2.32 |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
59342-6 |
Tadalafil |
MCnc |
Bld |
Pt |
Qn |
|
|
ACTIVE |
Tadalafil [Mass/volume] in Blood |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
10 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59342-6 |
|
|
|
|
Both |
|
|
|
0 |
Tadalafil Bld-mCnc |
|
|
|
N |
|
Blood; Cialis; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; WB; Whole blood |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59343-4 |
Tadalafil |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Tadalafil [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
10 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59343-4 |
|
|
|
|
Both |
|
|
|
0 |
Tadalafil SerPl-mCnc |
|
|
|
N |
|
Cialis; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59344-2 |
Tadalafil |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Tadalafil [Mass/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
10 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59344-2 |
|
|
|
|
Both |
|
|
|
0 |
Tadalafil Ur-mCnc |
|
|
|
N |
|
Cialis; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59345-9 |
Endoxifen |
MCnc |
Bld |
Pt |
Qn |
|
|
ACTIVE |
Endoxifen [Mass/volume] in Blood |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
1 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59345-9 |
|
|
|
|
Both |
|
|
|
0 |
Endoxifen Bld-mCnc |
|
|
|
N |
|
4-Hydroxy-N-desmethyltamoxifen; Blood; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; Tamoxifen metabolite; WB; Whole blood |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59346-7 |
4-Hydroxy-Tamoxifen |
MCnc |
Bld |
Pt |
Qn |
|
|
ACTIVE |
4-Hydroxy-Tamoxifen [Mass/volume] in Blood |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
1 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59346-7 |
|
|
|
|
Both |
|
|
|
0 |
4OHTamoxifen Bld-mCnc |
|
|
|
N |
|
4OHTamoxifen; Blood; DRUG/TOXICOLOGY; Drugs; Hydrox; Level; Mass concentration; Nolvadex; OH; Point in time; QNT; Quan; Quant; Quantitative; Random; Tamoxifen metabolite; WB; Whole blood |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59347-5 |
Tamoxifen |
MCnc |
Bld |
Pt |
Qn |
|
|
ACTIVE |
Tamoxifen [Mass/volume] in Blood |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
1 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59347-5 |
|
|
|
|
Both |
|
|
|
0 |
Tamoxifen Bld-mCnc |
|
|
|
N |
|
Blood; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Nolvadex; Point in time; QNT; Quan; Quant; Quantitative; Random; WB; Whole blood |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59348-3 |
Nortamoxifen |
MCnc |
Bld |
Pt |
Qn |
|
|
ACTIVE |
Nortamoxifen [Mass/volume] in Blood |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
1 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59348-3 |
|
|
|
|
Both |
|
|
|
0 |
Nortamoxifen Bld-mCnc |
|
|
|
N |
|
Blood; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; N-desmethyltamoxifen; Point in time; QNT; Quan; Quant; Quantitative; Random; Tamoxifen metabolite; WB; Whole blood |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59349-1 |
Endoxifen |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Endoxifen [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
1 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59349-1 |
|
|
|
|
Both |
|
|
|
0 |
Endoxifen SerPl-mCnc |
|
|
|
N |
|
4-Hydroxy-N-desmethyltamoxifen; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Tamoxifen metabolite |
2.73 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
5935-2 |
Benzoylecgonine |
MCnc |
Urine |
Pt |
Qn |
|
|
DEPRECATED |
Deprecated Benzoylecgonine [Mass/volume] in Urine |
|
DEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
5935-2 |
|
|
|
|
|
|
|
|
0 |
Deprecated BZE Ur-mCnc |
|
|
|
|
|
BEC; BEG; Benz; Benzoylec; BZE; Cocaine degradation production; Cocaine metabolite; Crack metabolite; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.36 |
1.0d |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
59350-9 |
4-Hydroxy-Tamoxifen |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
4-Hydroxy-Tamoxifen [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
1 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59350-9 |
|
|
|
|
Both |
|
|
|
0 |
4OHTamoxifen SerPl-mCnc |
|
|
|
N |
|
4OHTamoxifen; DRUG/TOXICOLOGY; Drugs; Hydrox; Level; Mass concentration; Nolvadex; OH; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Tamoxifen metabolite |
2.73 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59351-7 |
Nortamoxifen |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Nortamoxifen [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
1 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59351-7 |
|
|
|
|
Both |
|
|
|
0 |
Nortamoxifen SerPl-mCnc |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; N-desmethyltamoxifen; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Tamoxifen metabolite |
2.73 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |